You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Article info

Article menu

Download PDFPDF

XML
Basic tumor immunology
Original research
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Authors

  • Rui Yang Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Samah Elsaadi Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Kristine Misund Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Pegah Abdollahi Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Esten Nymoen Vandsemb Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Siv Helen Moen Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Anna Kusnierczyk PROMEC, Department for Clinical and Molecular Medicine, NTNU, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Geir Slupphaug PROMEC, Department for Clinical and Molecular Medicine, NTNU, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Therese Standal Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway CEMIR (Centre of Molecular Inflammation Research), Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Anders Waage Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway Department of Hematology, St. Olavs Hospital, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Tobias S Slørdahl Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway Department of Hematology, St. Olavs Hospital, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Torstein Baade Rø Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway Children’s Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Even Rustad Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Anders Sundan Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway CEMIR (Centre of Molecular Inflammation Research), Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway PubMed articlesGoogle scholar articles
  • Carl Hay Oncology R&D, AstraZeneca Medimmune, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Zachary Cooper Oncology R&D, AstraZeneca Medimmune, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Alwin G Schuller Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Richard Woessner Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Alexandra Borodovsky Bioscience, AstraZeneca R&D Boston, Waltham, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Eline Menu Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussel, Massachusetts, Belgium PubMed articlesGoogle scholar articles
  • Magne Børset Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  • Anne Marit Sponaas Center for Myeloma Research, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Anne Marit Sponaas; anne-marit.sponaas{at}ntnu.no
View Full Text

Citation

Yang R, Elsaadi S, Misund K, et al
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
Journal for ImmunoTherapy of Cancer 2020;8:e000610. doi: 10.1136/jitc-2020-000610

Publication history

  • Accepted April 1, 2020
  • First published May 14, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.